Cellevate, a biotech firm focused on next-generation cell culture systems, has successfully scaled up its Cellevat3d nanofiber microcarriers, thanks to funding from Vinnova/STUNS Life Science. The research was conducted at the Testa Center in Uppsala, Sweden, utilizing the 10-liter Xcellerex XDR-10 single-use stirred tank bioreactor from Cytiva.
 
The nanofiber-based Cellevat3d microcarriers could revolutionize bioprocessing. They boast up to 60 times the surface area of conventional carriers, facilitating a genuine three-dimensional cell culture environment that remarkably boosts viable cell densities and viral vector outputs in stirred tank reactors. Cellevate anticipates the launch of Cellevat3d nanofiber microcarriers in early November 2024.
 
“Scaling up at Testa Center in 10 L stirred tank bioreactor with our new category of nanofiber-based cell culture systems, while maintaining all the cell culture parameters unchanged from lab scale, is a great achievement. The study also demonstrated the ease of use and ease of implementation in bioreactors, and our ability to meet industrial bioprocessing scale up demand. We have now added the last piece of the puzzle in securing the success of the global commercial launch of the world’s first nanofiber-based cell culture systems designed to boost viral vector productivity – the global commercial launch will occur on November 4th at BIO-Europe in Stockholm,” said Laura Chirica, CEO of Cellevate.
 
“We’re thrilled to have supported Cellevate in their recent 3-week project at Testa Center which utilized our XDR10 bioreactor to scale up mammalian adherent cells. It’s fantastic to see innovative biotech companies like Cellevate leveraging our facilities to push the boundaries of cell culture technology. We’re proud to play a part in fostering advancements that help accelerate novel biotherapies development and production,” added Jesper Hedberg, CEO, Testa Center.